HEALTHCARE

A biotechnology company that uses its BioFM biological foundation model platform to discover targets and design genetic medicines. It runs its own drug discovery programs and research partnerships rather than selling a software product that businesses can sign up to.

SPEC SHEET

PRICE
Enterprise
SET-UP
Advanced
DATA
No AU option published
FOUNDED
2014
HQ
Toronto, Canada
WEBSITE
deepgenomics.com
REVIEWED
October 2026

001 / WHAT IT DOES

  1. 01BioFM biological foundation model platform for target and molecule discovery
  2. 02Focus on RNA biology and genetic medicines
  3. 03In-house drug discovery programs
  4. 04Research partnerships and licensing with pharmaceutical companies
  5. 05Prediction of how genetic variants affect RNA processing

BEST FOR

  • Pharmaceutical companies seeking genetic medicine discovery partners
  • Biotech firms exploring RNA-targeted therapeutic programs
  • Research institutes interested in AI-led target discovery collaborations

TYPICAL USES

Identifying new drug targets from genetic dataDesigning RNA-based therapeutic candidatesResearch partnerships with pharmaceutical companiesPredicting how genetic variants affect RNA processing

002 / THE HONEST TAKE

STRENGTHS

  • +Specialised in RNA biology and the design of genetic medicines
  • +Builds its own biological foundation models
  • +Operates as a research partner for pharmaceutical drug discovery programs
  • +Established research team with published work

WATCH OUTS

  • –No self-serve product or software subscription for businesses to buy
  • –Only relevant to drug discovery organisations
  • –Partnership terms are negotiated case by case with each organisation

003 / FOR AUSTRALIAN BUSINESSES

No AU option published

No Australian hosting option is published, so assume data is stored and processed overseas.

Deep Genomics does not offer a hosted product, so there is no public data residency option to choose. Data handling is set out in each research collaboration agreement. Australian partners sharing human genomic or clinical data should negotiate where data is stored and processed, de-identification standards, permitted uses, and ethics approvals before any transfer, as genomic data is sensitive information.

PRIVACY ACT & PRACTICAL NOTES

Deep Genomics is relevant mainly to Australian biotech companies, universities and medical research institutes looking at drug discovery partnerships, not to general businesses. Any collaboration involving human genomic data raises Privacy Act 1988 obligations for sensitive information, as well as ethics approvals under the National Statement on Ethical Conduct in Human Research. Candidates reaching clinical trials in Australia follow TGA and ethics committee processes. Check intellectual property ownership carefully in any partnership agreement.

Client data that can't leave Australia? There are ways to get the same job done onshore.

See private AI →

004 / WHAT IT COSTS

Enterprise

There is no product to buy or subscribe to. Access to its platform is through research collaborations and licensing deals with pharmaceutical and biotech organisations. Enquiries go through deepgenomics.com.

Check current prices on deepgenomics.com ↗︎

005 / CONNECTS WITH

No integrations listed in our review. Check the vendor for an API or connectors.

Want it wired into your CRM, inbox or Xero? That's what we build.

006 / ALTERNATIVES

Also worth a look

Also compared against: Insilico Medicine, Recursion, Isomorphic Labs, Numerion Labs.

007 / QUESTIONS

Anything else is quicker to answer on a call. Thirty minutes, free, with the people who would build it.

No. Deep Genomics is a drug discovery company, not a software vendor. Its BioFM platform supports its own programs and research partnerships. Organisations interested in working with it need to approach the company about a collaboration or licensing arrangement.

We set up and connect tools like this for Australian businesses, with the privacy settings done right from day one.

Book a free call→